MIR and TMD Form Alliance to Broaden Services

Wilbur Leopold, president of MIR Preclinical Services (MIR), a Michigan-based corporation, and Sarah Bacus, founder, CEO and CSO of Targeted Molecular Diagnostics (TMD), an Illinois limited liability company, today announced the companies have formed a strategic alliance to offer greater services and cost savings to clients. MIR is a contract research organization specializing in the preclinical evaluation of novel anti-tumor agents. TMD is a diagnostics development organization with extensive biomarker assay experience in oncology.

PrimeZone (http://www.primezone.com/newsroom/news_releases.mhtml?d=75780)